1,000
Participants
Start Date
February 1, 2018
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
Immune checkpoint inhibitor
Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Groupe Hospitalier Pitie-Salpetriere
OTHER